For several decades, studies with classical psychedelics have been significantly hampered by their legal status. Recently, researchers have begun to re-examine their therapeutic value launching a number of new small-scale studies, which have provided a substantial body of evidence for their efficacy and acceptable safety profile in the treatment of several psychiatric conditions such as depression, anxiety disorders and addictions.
What are the mechanisms of action of these substances? What makes them special in comparison to other psychoactive drugs? Finally, what is the context, indications and contraindications for psychedelic-assisted therapy? Can we call it an "evidence-based approach"? These and other related questions will be the topic of discussion in the present event.
The event is free of charge and no registration is required. Seats are however limited; it is advised to arrive early to secure a seat.